Ronald A. Matricaria Institute of Molecular Medicine at Phoenix Children's Hospital
Molecular, or personalized, medicine uses genetic information to determine the right treatment for the right patient at the right time.
By studying a patient's genetic makeup, researchers can identify their susceptibility to disease, predict their response to a particular drug and match the patient with a personalized therapy.
Challenges with existing molecular medicine programs include:
- The amount of time that it takes to develop a new drug or treatment.
- The majority of all medications used for children have been approved only for adult indications.
- Research and development of novel treatments for pediatric diseases have fallen short over past decades.
New collaboration brings new hope to children
Phoenix Children’s Hospital announced the creation of the Ronald A. Matricaria Institute of Molecular Medicine on Dec. 4, 2012, with the goal to unlock genetic codes and develop drug therapies to improve the outcome for thousands of young patients.
A founding gift by Ronald A. Matricaria provided the initial investment to establish the Institute. Matricaria is a member of the Phoenix Children’s Hospital board of directors and former chairman/CEO of St. Jude Medical, Inc. Additional funding for the $50 million venture will come from philanthropic contributions and grant revenue.
A critical component to this venture is Phoenix Children’s collaborative relationships with leading bioscience institutions.
- The University of Arizona College of Medicine – Phoenix brings academic and research programs, as well as academic credentials necessary to recruit and develop a research program.
- The Translational Genomics Research Institute (TGen) contributes deep expertise in genomics and bioinformatics and sophisticated laboratory space.
The Institute is a critical piece in the development Phoenix Children's emerging academic medical program and will position the Hospital to become national contributors and leaders in molecular medicine.
A distinguished team works to cure pediatric diseases
The team of scientists and staff focus on pediatric cancers in phase one, and will expand to other pediatric diseases over time.